

Supplementary material

Weryński P, Skorek P, Wójcik A, et al. Recent achievements in transcatheter closure of ventricular septal defects: a systematic review of literature and a meta-analysis. *Kardiol Pol.* 2021; 79: 161-169. doi:10.33963/KP.15708

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.



PRISMA 2009 Flow Diagram




Figure S1 The PRISMA Flow Diagram with study algorithm [5]. <https://creativecommons.org/licenses/by/4.0/>
Modified from: Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. *Open Med.* 2009; 3: 123-130.

Table S2 Summary of analyzed studies.

FIRST AUTHOR	PPUBLISHED YEAR	COUNTRY	TOTAL NO OF PATIENTS	DEVICE TYPES	VSD TYPE	AGE OF PATIEN TS [YEARS]	TIME OF FOLLOW- UP [MONTHS]
Mijangos-Vázquez R et al. [8]	2020	Mexico, Egypt	119	ADO I (n=55), ADO II (n=51), AVP (n= 12)	pmVSD	5# (0.7- 54)	36 (25.7) *
Tanidir IC et al. [9]	2020	Turkey	98	LifeTech™ multifunctional occluder device (MF-Konar),	pmVSD (n=84), mVSD (n=14) 14 pts	3,8# (range 0.45-50)	7.47 (4.97)*
Shah JH et al. [10]	2020	India	376	Cardi-O-Fix VSD occluder, Shanghai shape memory alloy occluder, ADO I	pmVSD	8.67 (3)*	78#
Houeijeh A et al. [11]	2020	France	46	Nit-Occlud Lé VSD coil	pmVSD	13.9#	27 (range 2- 50) #

Haddad RN et al. [12]	2019	Lebanon	20	KONAR-MF™ VSD occluder	pmVSD	6.4#	8.2 (3)*
Li H et al. [13]	2019	China	253	Amplatzer Membranous VSD Occluder (n=7), Amplatzer-like occluders including Membranous Symmetric VSD Occluder (n=167), Cera™ Membranous VSD (Symmetric) Occluder (n=79 pts)	pmVSD	3.5#	36 (range 6– 60)#
Haddad RN et	2019	Lebanon	51	ADO I (n=8), ADO II (n=27), AmplatzerMus	pmVSD	7.4 (6.9)* 2-29.8) #	6.47 (range 2-29.8) #

al.[14]				cular VSD Occluder (n=17)			
Bu H et al. [15]	2019	China	46	The VSD occluder (Shanghai Shape Memory Alloy Co, Ltd., Shanghai, China)	pmVSD	6.5 (2.3)*	21.8 (4.7)*
Kouakou NYN et al. [16]	2019	Côte d'Ivoire, South Korea	6	ADO I, ADO II, AVP II, Cocoon membranous VSD occluder	Postope rative VSD	17.7#	33#
Pillai AA et al. [17]	2019	India	49	Amplatzer membranous VSD occluder	pmVSD	1.5#	20 (range 6- 72.5)*
Huang Y et al. [18]	2019	China	22	ADO I	doubly committ ed subarter	10# (range 1- 57)	12.3*

					ial VSD		
Shrestha M et al.[19]	2019	Thailand	133	PFM coil (n=59), ADO (n=22), ADO II (n=20), CVO- ME (n=6), CDO (n=5), LMFO (n=5), LVO-MS (n=6) and 6 other devices	pmVSD	7# (0.75- 28)	12
Udink Ten Cate FEA et al. [20]	2019	Germany, Netherland s, Egypt, India,	222	ADO I (n=174), Liftech duct occluder (n=44)	pmVSD	7#	6 (range 6 months – 6 years)##
He L et al. [21]	2019	China	20	improved PDA occluder (Starway Medical Technology, Inc., Beijing,	pmVSD	20.7 (12.3)*	28,8*

				China)			
Esmaeili A et al. [22]	2018	Germany	15	ADO II	pmVSD	5# (range 0.3-21)	30*
Wang S et al. [23]	2018	China	118	Occluder from Starway Medical Technology Inc., Beijing, China	pmVSD	11.7 (12.5)*	40.8 (27.6)*
Park H et al. [24]	2018	South Korea	13	The Cocoon VSD occluder	pmVSD (n=9), mVSD (n=2), postoperative VSD (n=2)	5.8# (range 0.58-48)	10 (6)*
Ghosh S et al. [25]	2018	India	19	ADO-II (n=17), ADO-I (n=2)	pmVSD (n=11), subaorti	8 (4)*	18 (range 12–36)*

					c VSD (n=6), subarterial VSD (n=2)		
Nguyen HL et al. [26]	2018	Vietnam, South Korea, India	386	ADO (n=7), Cocoon Duct Occluders (n=149), Cera PDA Occluders (n=69), Nit- Occlud Lé VSD coil (n=71)	pmVSD	15 (12.6) vs 16.8 (14)*	61.4 (24.1)*
Mandal KD et al. [27]	2018	China	186	Lifetech Scientific Shenzhen Co, Ltd (Shenzhen, China), Shanghai pmVSD occluder made by Shanghai	pmVSD	5.4 (2.8)*	18,4 (range 6-120)*

				shape memory alloy Co, Ltd (Shanghai, China)			
Narin N et al. [28]	2018	Turkey	12	ADO II, ADO II-additional size	pmVSD (n=8), mVSD (n=3), postoperative VSD (n=1)	0.67*	8,5#
Zhao LJ et al. [29]	2018	China	102	ADO (n=250) , conventional membranous ventricular septal occluder (n=52)	pmVSD	5.0 (3.7) vs 4.8 (2.8)*	26,2#
El Shedoudy S et al. [30]	2018	Egypt	80	Nit-Occlud Lé VSD Coil	pmVSD (n=77), mVSD (n=2), Gerbode	5.34 (3)	36

					defect (n=1)		
He L et al. [31]	2018	China	121	Modified self-expandable double-disk occluder (ShangHai Shape Memory Alloy, Shanghai, China)	pmVSD	4#	24
Lin MT et al. [32]	2017	Taiwan	105	ADO I (n=67), ADO (n=II 34)	pmVSD	19.5#	24*
Shyu TC et al. [33]	2017	Taiwan	16	ADO	subarterial VSD (n=9) supracristal, (n=7) intracristal	35.6# (range 3-65.6)	12

El-Sisi A et al. [34]	2017	Egypt	30	ADO I (n=13), ADO II (n=17)	pmVSD	4# (range 1-13)	11(range 6–24) *
Haas NA et al. [35]	2017	Germany, Netherland s, Belgium, Ukraine, Russia, Switzerlan d, Italy	111	Nit-Occlud Lé VSD coil	pmVSD (n=81), mVSD (n=30)	5.1#	31.3#
Zhou W et al. [36]	2016	China	12	LifeTech (n=7), ADO II (n=1), AGA PLUG II (n=1), Shanghai shapememory (n=3)	Postope rative VSD	8.13 (5.39)*	12
Hua N et al. [37]	2016	United States of America	16	AVP-II	pmVSD	2.56 (range: 0.5- 27.3)#	12#
Thakkar B et al.	2016	India	297	SHSMA-179, Cardio-o-fix-85	pmVSD	9 (3.12)* (13.15)*	18.23

[38]				(n=257), ADO I (n=33)			
Polat TB et al. [39]	2016	Turkey	26	ADO II	pmVSD (n=21), mVSD (n=3), postoperative (n=2)	2.7 (2.8)*	12#
Wang J et al. [40]	2016	China	337	symmetrical concentric pmVSD occlude (n=302), asymmetrical concentric pmVSD occlude (n=35) (Starway Medical Technology, Inc . , Beijing, China)	pmVSD	29.2 (10.7)*	71#

Bai Y et al. [41]	2016	China	117	MDVOs (Shanghai Shape Memory Alloy Ltd, Shanghai, China) according to the Amplatzer occluder	pmVSD	31.1 (12.5)*	110#
Ghaderian M et al. [42]	2015	Iran	110	Amplatzer VSD Occluder.	pmVSD	4.7 (5.6)*	10.9 (3.6)*
Chen F et al. [43]	2015	China	38	The zero eccentric VSD occluder was chosen for closure (Shanghai Shape Memory Alloy Ltd, Shanghai, China)	intracris- tal VSD with aortic cusp prolapse d	25.3 (14.0)*	14.2#

Ghaderian M et al. [44]	2015	Iran	28	ADO	pmVSD	$4.7 \pm 6.3^*$	8.3 (3.6)*
Chen GL et al. [45]	2015	China	65	The HeartR™ VSD Occluder (Lifetech Scientific (Shenzhen) Corporation, P.R.C)	intracris tal VSD (n=47), pmVSD (n=18)	6 (3)*	12
Mahimara ngaiyah J et al. [46]	2015	India	126	Lifetech Patent ductus arteriosus occluders (n=81), ADO II (n=45)	pmVSD	8#	12
Kanaan M et al. [47]	2015	Germany	31	ADO II	pmVSD (n=20), mVSD (n=10), ruptured sinus	2,52#	41#

					valsalva (n=1)		
Vijayalakshmi IB et al. [48]	2015	India	12	ADO II	Gerbode defects	6,7*	9,5#
Narin N et al. [49]	2015	Turkey	21	ADO II	pmVSD (n=19), mVSD (n=2)	8.7 (4.51)*	12
Odemis E et al. [50]	2014	Turkey	20	Nit-Occlud Lé VSD coil	pmVSD (n=19), ventricular septal eurysmal tissue (n=1)	7.3 (4.0)*	12.3 (6.6)*
Tzikas A et al. [S51]	2014	Canada	19	Amplatzer Membranous VSD Occluder	pmVSD (n=16), residual pmVSD	6#	14 (3)*

				2	(n=2), residual Gerbode defect (n=1)		
--	--	--	--	---	--	--	--

*mean (Standard deviation); #median (Interquartile range); ADO- AMPLATZER™ Duct Occluder; AVP- AMPLATZER™ Vascular Plug; mVSD- muscular ventricular septal defect; NG- not given-number of cases; pmVSD- perimembranous ventricular septal defect; VSD- ventricular septal defect.